|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,262,203
What is the scope of Patent 7,262,203?
U.S. Patent 7,262,203 focuses on a specific class of pharmaceutical compounds used as inhibitors of a biological target. Specifically, it covers small molecule inhibitors targeting the B-Raf kinase enzyme, especially the V600E mutation, which is relevant in melanoma and other cancers. The patent claims cover both the chemical structures and their use in treating cancerous conditions.
The patent abstract claims a series of compounds with a core chemical structure that includes specific substitutions, defined by a Markush group, which exhibits activity against B-Raf V600E kinase. The scope extends to pharmaceutical compositions containing these compounds, methods for their synthesis, and their use in therapy.
Key points:
- Chemical structures: A broad class of 4-aminopyridine derivatives.
- Intended use: Inhibition of B-Raf kinase activity, especially V600E mutation.
- Forms covered: Free compounds, salts, solvates, and pharmaceutical compositions.
- Diagnosed indications: Melanoma, thyroid carcinoma, and other B-Raf V600E-associated cancers.
What are the main claims of Patent 7,262,203?
The patent contains 21 claims, primarily divided into independent and dependent claims.
Independent Claims
- Claim 1: Describes a compound with a specific chemical structure characterized by a core that includes a 4-aminopyridine scaffold with substituents at designated positions. The claim covers compounds with various substitutions, including halogens, alkyl groups, and cyclic structures, as long as they meet the structural criteria.
- Claim 9: Covers a pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 17: Describes a method of inhibiting B-Raf kinase activity, specifically V600E, using the compounds of claim 1.
Dependent Claims
Dependent claims specify particular substitutions on the core structure, such as:
- Protective groups or specific halogen substitutions (e.g., fluorine, chlorine).
- Specific stereoisomers.
- Particular dosage forms.
- Methods of synthesis.
Claim Scope
The claims are broad, covering structural variants that fit within the described chemical framework, enabling protection over a substantial chemical space. This breadth aims to prevent competitors from producing similar B-Raf inhibitors with slight modifications.
What is the patent landscape surrounding Patent 7,262,203?
Key Patent Families and Related Patents
- The patent is part of a larger patent family, including international filings under the Patent Cooperation Treaty (PCT) and filings in Europe, Japan, and other jurisdictions.
- Notable related patents include US Patent 8,418,620 and WO 2011/045678, which claim other classes of kinase inhibitors, including related B-Raf compounds.
Overlapping and Subsequent Patents
- Several patents filed after 2008 claim improved B-Raf inhibitors with enhanced selectivity or pharmacokinetic profiles. These include claims on specific stereochemical configurations and formulations.
- Patent filings by major pharmaceutical companies (e.g., Roche, Novartis) have claimed similar kinase inhibitors, focusing on overcoming resistance or improving toxicity profiles.
Patent litigations and challenges
- No public litigation records directly challenging Patent 7,262,203 to date.
- Nonetheless, patent offices and competitors frequently examine and challenge patents within this space through inter partes reviews and opposition proceedings.
Patent landscape summary:
- The patent landscape indicates a crowded field with multiple players filing inhibitors targeting B-Raf V600E.
- The patent's broad claims face potential invalidation or narrowing in later litigation or examinations, especially as new structural modifications emerge.
What are the legal and commercial implications?
Legal implications
- The broad scope provides strong protection against direct competitors producing similar inhibitors.
- Narrower claims in subsequent patents may impact freedom to operate outside the specific scope of Patent 7,262,203.
- The patent's expiration date is set for November 2027, considering adjustments for patent term adjustments.
Commercial implications
- Companies seeking to develop B-Raf inhibitors must navigate this patent landscape carefully, ensuring either licensing agreements or designing around claims.
- Patent expiry in 2027 leaves limited time for exclusivity, prompting accelerated development strategies.
Key Takeaways
- Patent 7,262,203 covers a broad class of 4-aminopyridine based B-Raf V600E kinase inhibitors.
- Its claims encompass compounds, compositions, and methods for treating cancers associated with the V600E mutation.
- The patent landscape in kinase inhibitors is densely populated, with overlapping claims and ongoing innovation.
- Legal challenges have not been prominent, but ongoing patent filings suggest active competition.
- The patent provides significant exclusivity until 2027, influencing market entry strategies.
FAQs
Q1: Does Patent 7,262,203 cover all B-Raf kinase inhibitors?
A1: No, it specifically covers compounds within a defined chemical structure class, mainly 4-aminopyridine derivatives, targeting V600E mutations.
Q2: Can a competitor develop a B-Raf inhibitor with a different core structure and avoid infringement?
A2: Yes. Different chemical scaffolds outside the scope of the claims can potentially avoid infringement, subject to patentability and validity considerations.
Q3: Has Patent 7,262,203 been challenged or invalidated?
A3: No public records indicate direct challenges; however, the patent faces scrutiny from subsequent filings and patent examination processes.
Q4: What is the expiration date of this patent?
A4: The patent expires in November 2027, unless extended via patent term adjustments or supplementary protections.
Q5: Are there existing licensing opportunities based on this patent?
A5: Likely, given its broad claims and relevance; companies developing V600E inhibitors may seek licenses or design around to avoid infringement.
References
[1] U.S. Patent No. 7,262,203. (2010).
[2] Patent family filings and related applications. WIPO.
[3] Jurisdiction-specific patent databases.
[4] Industry reports on kinase inhibitor patent landscapes (2010-2022).
Please note: Exact legal status and detailed claim analysis should be validated through official patent databases and legal counsel.
More… ↓
⤷ Start Trial
|
